{
    "url_original": "https://www.wsj.com/articles/halozyme-therapeutics-nears-deal-to-buy-antares-pharma-11649840401?mod=business_lead_pos2",
    "url": "halozyme-therapeutics-nears-deal-to-buy-antares-pharma-11649840401",
    "title": "Halozyme Therapeutics Nears Deal to Buy Antares Pharma",
    "sub_head": "The deal, which could be announced Wednesday, would value Antares at roughly $960 million, according to people familiar with the matter",
    "category_1": "Deals",
    "image_1_url": "https://images.wsj.net/im-523709?width=860&height=573",
    "image_1": "im-523709.jpg",
    "time": "2022-04-13 05:00:00",
    "body": "Halozyme Therapeutics Inc.  is close to a nearly $1 billion deal to buy specialty pharmaceutical company  Antares Pharma Inc.,  according to people familiar with the matter, in a move that would deepen its focus on drug delivery.<br />Halozyme would pay $5.60 a share in cash in a deal that could be announced Wednesday and value Antares at roughly $960 million, the people said."
}